The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global enteric disease testing market reached a value of US$ 3.87 Billion in 2020. Looking forward, IMARC Group expects the market to exhibit stable growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Enteric diseases are caused by the entering of microorganisms, such as viruses, bacteria and parasites, in the body through the mouth. These pathogens can be acquired through contaminated food and water or by encountering feces of an animal or infected person. The common symptoms of enteric diseases are abdominal cramps, vomiting, nausea and anorexia that can lead to loss of fluids and essential nutrients from the body. In recent years, advancements in diagnostic technologies have revolutionized enteric disease testing and significantly increased the detection rates in symptomatic individuals.
The improper drainage and sanitation systems, unsafe drinking water and unhygienic living conditions can significantly increase the risk of enteric diseases. This, along with a substantial rise in medical tourism in recent years, represents one of the key factors impelling the market growth. Besides this, the increasing awareness among individuals about the benefits of early diagnosis is acting as another major growth-inducing factor. Apart from this, several international agencies, such as the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), are conducting awareness programs and setting up healthcare camps in different countries to promote the testing of enteric diseases. Moreover, several key players are focusing on the commercialization of novel testing technologies, which is contributing to the market growth. Furthermore, as human coronaviruses cases are associated with enteric diseases, several healthcare institutes are conducting studies to find interrelation between enteric disease and the coronavirus disease (COVID-19).
IMARC Group provides an analysis of the key trends in each sub-segment of the global enteric disease testing market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type, technique, disease type and end-user.
Breakup by Product Type:
Breakup by Technique:
Breakup by Disease Type:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomérieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, Technique, Disease Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomérieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at